[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-arterial-hypertension-associated-with-connective-tissue-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-arterial-hypertension-associated-with-connective-tissue-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100474797","right-ventricle-lipid-in-pulmonary-arterial-hypertension-pah-100474797",false,"NCT05462574","Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)","Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension (PAH)","Inclusion criteria:\n\n* ≥ 18 years old\n* Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations.\n* Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted.\n* WHO Functional Class I-III\n* Ambulatory\n* Able to have an MRI\u002FMRS, perform a 6MWD test, and cardiopulmonary exercise test\n\nExclusion criteria:\n\n* Pregnancy\n* Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins\n* WHO Functional class IV heart failure\n* Requirement for continuous oxygen\n* Unable to have an MRI\u002FMRS, perform a 6MWD test, or cardiopulmonary exercise test.\n* Patients with implanted\u002Fembedded ferromagnetic material that would preclude cardiac MRI","ALL","18 Years",{"count":19,"type":20},75,"ESTIMATED","OBSERVATIONAL","The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.",[24,25,26],"Idiopathic Pulmonary Arterial Hypertension","Heritable Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension Associated With Connective Tissue Disease","RECRUITING","2026-05-26",{"date":30,"type":31},"2026-05-29","ACTUAL",{"date":33,"type":31},"2023-01-17",{"date":35,"type":20},"2027-09-30",{"name":37,"class":38},"Vanderbilt University Medical Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":39},"100609664","rutgers-university-study-of-the-genetics-of-pulmonary-hypertension-100609664","NCT07217522","Rutgers University Study of the Genetics of Pulmonary Hypertension","RUGCC-PH","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* able to understand and follow written instructions in English\n* have access to the internet and a computer, laptop, tablet or smart phone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home\n* willing to complete a survey with questions about health related to the study of pulmonary hypertension.\n\nExclusion Criteria:\n\n* Age 17 or below\n* Not currently living in the United States\n* Not able to participate in an online research study in English",true,{"count":49,"type":20},10000,"The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligible, and a diagnosis of PH is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.",[52,53,54,26,55,56,57,58],"Pulmonary Hypertension","Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)","Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)","Pulmonary Arterial Hypertension of Congenital Heart Disease","Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension","2025-10-30",{"date":61,"type":31},"2025-11-03",{"date":63,"type":31},"2025-08-23",{"date":65,"type":20},"2027-12-31",{"name":67,"class":38},"Rutgers, The State University of New Jersey",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":39},"100607150","clinical-features-and-prognosis-of-takayasus-arteritis-with-pulmonary-arteries-involvement-100607150","NCT07184814","Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement","CAPTAIN","Inclusion Criteria:\n\n* Hospitalized between Jan 1, 2016 and Dec 31, 2026\n* Diagnosed with TAK according to the modified Ishikawa criteria and\u002For 1990 American College of Rheumatology criteria and\u002For 2022 ACR\u002FEULAR criteria\n* Diagnosed with pulmonary artery involvement using computed tomography pulmonary angiography or transcatheter pulmonary angiography\n* Patients without aortic or primary branch involvement who nonetheless exhibited both clinical features and computed tomography-confirmed evidence of pulmonary artery involvement (PAI), after exclusion of other diseases causing pulmonary artery stenosis or occlusion\n\nExclusion Criteria:\n\n* Patients with PAI caused by non-TAK diseases such as other types of vasculitis, fibrosing mediastinitis, pulmonary artery sarcoma, pulmonary sarcoidosis or chronic thromboembolic pulmonary hypertension",{"count":76,"type":20},150,"The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).",[79,26],"Takayasu Arteritis With Pulmonary Artery Involvement","2025-09-19",{"date":82,"type":31},"2025-09-22",{"date":84,"type":31},"2016-01-01",{"date":86,"type":20},"2026-12-31",{"name":88,"class":38},"China-Japan Friendship Hospital"]